BACKGROUND AND OBJECTIVES: MicroRNA-203 (miR-203) serves as a tumor suppressor or a tumor promoter in different human malignancies. However, its involvement in human gliomas is still unclear. The aim of this study was to investigate the clinical significance of miR-203 expression in gliomas. METHODS: Real-time quantitative PCR was employed to measure the expression level of miR-203 in clinical glioma tissues. RESULTS: The expression of miR-203 was reduced in high WHO grade glioma tissues compared with that in low WHO grade and normal brain tissues, and decreased with ascending tumor WHO grades (P < 0.001). The reduced miR-203 expression in gliomas was significantly associated with higher WHO grade (P < 0.001), lower KPS score (P = 0.008) and poorer disease-specific survival of patients (P = 0.001). More importantly, subgroup analyses according to tumor WHO grade revealed that the disease-specific survival of patients with low miR-203 expression in high WHO grades (III-IV) subgroup was significantly shorter than those with high miR-203 expression (P < 0.001), but no significant difference was found for patients in WHO grades I-II subgroup (P = 0.08). CONCLUSION: Our data validate an important clinical significance of miR-203 in gliomas, and reveal that it might be an intrinsic regulator of tumor progression and a potential prognostic factor for this dismal disease.
BACKGROUND AND OBJECTIVES:MicroRNA-203 (miR-203) serves as a tumor suppressor or a tumor promoter in different humanmalignancies. However, its involvement in humangliomas is still unclear. The aim of this study was to investigate the clinical significance of miR-203 expression in gliomas. METHODS: Real-time quantitative PCR was employed to measure the expression level of miR-203 in clinical glioma tissues. RESULTS: The expression of miR-203 was reduced in high WHO grade glioma tissues compared with that in low WHO grade and normal brain tissues, and decreased with ascending tumor WHO grades (P < 0.001). The reduced miR-203 expression in gliomas was significantly associated with higher WHO grade (P < 0.001), lower KPS score (P = 0.008) and poorer disease-specific survival of patients (P = 0.001). More importantly, subgroup analyses according to tumor WHO grade revealed that the disease-specific survival of patients with low miR-203 expression in high WHO grades (III-IV) subgroup was significantly shorter than those with high miR-203 expression (P < 0.001), but no significant difference was found for patients in WHO grades I-II subgroup (P = 0.08). CONCLUSION: Our data validate an important clinical significance of miR-203 in gliomas, and reveal that it might be an intrinsic regulator of tumor progression and a potential prognostic factor for this dismal disease.
Authors: Guan Sun; Shushan Yan; Lei Shi; Zhengqiang Wan; Nan Jiang; Min Li; Jun Guo Journal: Cancer Biother Radiopharm Date: 2015-03-26 Impact factor: 3.099
Authors: Simone Meidhof; Simone Brabletz; Waltraut Lehmann; Bogdan-Tiberius Preca; Kerstin Mock; Manuel Ruh; Julia Schüler; Maria Berthold; Anika Weber; Ulrike Burk; Michael Lübbert; Martin Puhr; Zoran Culig; Ulrich Wellner; Tobias Keck; Peter Bronsert; Simon Küsters; Ulrich T Hopt; Marc P Stemmler; Thomas Brabletz Journal: EMBO Mol Med Date: 2015-06 Impact factor: 12.137